Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: A quantitative literature review

Schizophrenia Bulletin

Volumn 38, Issue 5, 2012, Pages 1003-1011

  Sommer, Iris E ^a   Begemann, Marieke J H ^a   Temmerman, Anke ^a   Leucht, Stefan ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

augmentation; clozapine; resistant; schizophrenia

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMISULPRIDE; ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; CYCLOSERINE; FLUOXETINE; GLYCINE; HALOPERIDOL; LAMOTRIGINE; MIRTAZAPINE; PLACEBO; RISPERIDONE; SARCOSINE; SERINE; SULPIRIDE; TOPIRAMATE;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CITALOPRAM; CLOZAPINE; DIOXOLES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FRUCTOSE; HUMANS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE; TREATMENT OUTCOME; TRIAZINES;

EID: 84865334678     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr004     Document Type: Article

References (80)

1. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997;23:663-674.
2. McGlashan TH. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull. 1988;14:515-542.
3. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Economic grand rounds: cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry. 1990;41:850-854.
4. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry Suppl. 1994;25:18-21.
5. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;5:789-796.
6. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158:518-526.
7. Lewis SW, Barnes TRE, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32:715-723.
8. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-610.
9. Schulte PFJ. What is an adequate trial with clozapine? Clin Pharmacokinet. 2003;42:607-618.
10. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994;151: 1744-1752.
11. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients: i: Preliminary report. Psychopharmacology (Berl). 1989;99:S68-S72.
12. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients eligible for treatment with clozapine. Biol Psychiatry. 2001; 49:59-60.
13. Dickerson FB. Cognitive behavioural psychotherapy for schizophrenia: a review of recent empirical studies. Schizophr Res. 2000;43:71-90.
14. Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J. When symptoms persist: clozapine augmentation strategies. Schizophr Bull. 2001;27:615-628.
15. Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry. 2010;71:873-884.
16. Havaki-Kontaxaki BJ, Ferentinos PP, Kontaxakis VP, Paplos KG, Soldatos CR. Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. Clin Neuropharmacol. 2006;29:52-56.
17. Davis JM. The choice of drugs for schizophrenia. N Engl J Med. 2006;354:518-520.
18. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebocontrolled trial. Schizophr Res. 2007;92:90-94.
19. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354:472-482.
20. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol. 2007;27:198-204.
21. Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther. 2007;29:183-195.
22. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry. 1996;57:395-397.
23. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry. 1997;171:569-573.
24. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry. 1996;153:1625-1627.
25. Silver H, Kushnir M, Kaplan A. Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol Psychiatry. 1996;40:671-674.
26. Small JG, Klapper MH, Malloy FW, Steadman TM. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol. 2003;23:223-228.
27. Kando JC, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry. 1994;55:255-257.
28. Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychosis: a review. J Psychiatry Neurosci. 1992;17:1-14.
29. Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebocontrolled crossover trial. Biol Psychiatry. 2003;54:1241-1248.
30. Al-Semaan Y. Bromocriptine as adjunctive therapy to clozapine in treatment-resistant schizophrenia. Can J Psychiatry. 1996;41:484-485.
31. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 2000;157:826-828.
32. Carpenter WT, Breier A, Buchanan RW, Kirkpatrick B, Shepard P, Weiner E. Mazindol treatment of negative symptoms. Neuropsychopharmacology. 2000;23:365-374.
33. Peet M, Horrobin DF. E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyleicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res. 2002;36:7-18.
34. Chong SA, Remington G. Clozapine augmentation: safety and efficacy. Schizophr Bull. 2000;26:421-440.
35. Lerner V, Libov I, Kotler M, Strous RD. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28: 89-98.
36. Williams L, Newton G, Roberts K, Finlayson S, Brabbins C. Clozapine-resistant schizophrenia: a positive approach. Br J Psychiatry. 2002;181:184-187.
37. Crawford JM, Briggs CL, Engeland CG. Publication bias and its implications for evidence-based clinical decision making. J Dent Educ. 2010;74:593-600.
38. Remington G, Saha A, Chong S, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs. 2005;19:843-872.
39. Frances A, Docherty JP, Kahn DA. The expert consensus guideline series: treatment of schizophrenia. J Clin Psychiatry. 1996;57:1-50.
40. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2009;36:71-93.
41. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535 doi: 10.1136/bmj.b2535.
42. American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Organisation; 1994.
43. Lipsey MW, Wilson DB. Practical Meta-Analysis. Thousand Oaks, CA: Sage; 2001.
44. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
45. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:790-812.
46. Andreasen NC. Scale for the Assessment of Positive Symptoms (SANS). Iowa City, IA: University of Iowa; 1984.
47. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.
48. Dunlap WP, Cortina JM, Vaslow JB, Burke MJ. Metaanalysis of experiments with matched groups or repeated measures designs. Psychol Methods. 1996;1:170-177.
49. Shadish WR, Haddock CK. Combining estimates of effect size. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994:261-281.
50. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
51. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta Analysis Version 2. Engelwood, NJ: Biostat Inc; 2005.
52. Diaz P, Bhaskara S, Dursun SM, Deakin B. Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol. 2005;25:277-278.
53. Goff DC, Henderson DC, Evins AE, Amico E. A placebocontrolled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;45: 512-514.
54. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006;21:99-103.
55. Tiihonen J, Halonen P, Wahlbeck K. Topiramate add-on in treatment-resistant schizophrenia: a randomized, doubleblind, placebo-controlled, crossover trial. J Clin Psychiatry. 2005;66:1012-1015.
56. Zoccali R, Muscatello MR, Bruno A, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res. 2007;93:109-116.
57. Afshar H, Roohafza H, Mousavi G, et al. Topiramate addon treatment in schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. J Psychopharmacol. 2009; 23:157-162.
58. Muscatello MRA, Bruno A, Pandolfo G. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol. July 8, 2010; doi:10.117/0269881110372548.
59. Lan GX, Li ZC, Li L. A randomized, placebo-controlled clinical trial of combined citalopram and clozapine in the treatment of negative symptoms of schizophrenia. Chin Ment Health J. 2006;20:696-698.
60. Zoccali R, Muscatello MR, Cedro C, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2004; 19:71-76.
61. Berk M, Gama CS, Sundram S, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol. 2009;24:233-238.
62. Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry. 2004;56:441-446.
63. Anil Yagcioglu AE, Kiviricik Akdede BB, Turgut TI, et al. A Double-Blind Controlled Study of Adjunctive Treatment With Risperidone in Schizophrenic Patients Partially Responsive to Clozapine: efficacy and Safety. J Clin Psychiatry. 2005;66:63-72.
64. Josiassen RC, Joseph A, Kohegyi E, et al. A Clozapine Augmented With Risperidone in the Treatment of Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Trial. Am J Psychiatry. 2005;162:130-136.
65. Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol. 2007;27:582-589.
66. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):720-731.
67. Fleischhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13(8):1115-1125.
68. Mossaheb N, Sacher J, Wiesegger G, et al. Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia. Eur Neuropsychopharmacol. 2006; 16(suppl. 4):416.
69. Weiner E, Conley RR, Ball MP, et al. July 21, 2010. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacol. doi:10. 1038/npp.2010.101.
70. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol. 2001;21:484-487.
71. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. Dserine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 1999;156:1822-1825.
72. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry. 1999;156: 145-147.
73. Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006;60: 645-649.
74. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2008;41:24-28.
75. Wang J, Omori IM, Fenton M, Soares B. Sulpiride augmentation for schizophrenia. Schizophr Bull. 2010;36:229-230.
76. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic-a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand. 2009;119: 419-425.
77. Barbui C, Signoretti A, Mulè S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009;35:458-468.
78. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Paplos KG, Pappa DA, Christodoulou GN. Risperidone augmentation of clozapine: a critical review. Eur Arch Psychiatry Clin Neurosci. 2006;256:350-355.
79. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009;109: 10-14.
80. Trikalinos TA, Churchill R, Ferri M, et al. EU-PSI project. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol. 2004; 57:1124-1130.